Knowledge Library

Emerging Modalities in Drug Discovery

In this webinar, we present the latest advances and challenges facing researchers focused on new and emerging modalities in drug discovery. Topics include targeted protein degradation, targeted covalent inhibitors, and nucleic acid therapeutics. Our expert speaker, Dr. Tao Guo, discusses solutions for addressing the complexities in designing, synthesizing, and optimizing these molecules, with an added …Read More >

Resource Type: Latest Science Webinar
Resource Topic: Discovery Chemistry Oligonucleotides Small Molecules Targeted Protein Degradation

VIEW

Discovery and preclinical profile of LX-039, a novel indole-based oral selective estrogen receptor degrader (SERD)

WuXi AppTec scientists contributed to a study which identified a novel, indole-based, selective estrogen receptor degrader (SERD), designated LX-039. The authors show that LX-039 exhibits potent activity in ER degradation and proliferation assays. With favorable ADME/PK properties, LX-039 also exhibits higher efficacy in a tamoxifen-resistant MCF7 CDX model compared to fulvestrant, with up to 90% inhibition …Read More >

Resource Type: Latest Science Publication
Resource Topic: Biochemical Assays Cell-based Assays Discovery Chemistry Hit-to-Lead Lead Optimization Oncology Small Molecules

VIEW

Inhibition of the hERG potassium ion channel by non-nucleoside CMV polymerase antiviral inhibitors

WuXi AppTec scientists collaborated on a study to characterize a series of pyrroloquinoline derivatives that were designed and synthesized to understand the effect of various substitutions on human cytomegalovirus (HCMV) polymerase activity, antiviral activity, and hERG inhibition.  Results suggest that substitutions can be fine-tuned to reduce hERG inhibition while maintaining HCMV antiviral potency. The abstract …Read More >

Resource Type: Latest Science Publication
Resource Topic: Biochemical Assays Discovery Chemistry Hit-to-Lead Infectious Diseases Small Molecules

VIEW

Recent Advances in Library Synthesis to Accelerate Medicinal Chemistry Research

Learn how parallel medicinal chemistry (PMC) and high throughput experimentation (HTE) combined with machine learning can provide a more focused approach to target molecules, resulting in a more concentrated set of compounds to make the process of lead selection easier. Our experts show how PMC can shorten the turnaround time of the design-synthesis-test cycle, providing …Read More >

Resource Type: Webinar
Resource Topic: Discovery Chemistry Hit Finding Hit-to-Lead Small Molecules

VIEW

Research Chemistry Services

Delivering synthetic and medicinal chemistry solutions to global pharma and biotech customers for the discovery of hits, leads, and preclinical candidates. Check out our comprehensive panel of integrated, discovery chemistry services.

Resource Type: Brochure
Resource Topic: Discovery Chemistry Small Molecules

VIEW

Biophysical and Structural Biology Methods Enable Fragment-based Covalent Ligand Discovery of Human BTK

Drug Discovery Chemistry Conference 2023 Powerful biophysical and structural biology tools enable the study of large numbers of covalent fragments and are opening up new possibilities in the treatment of various diseases. Here, Dr. Moran Jerabek-Willemsen, Head of Biophysics & Screening in WuXi Biology reports the results of a covalent FBDD project on Bruton’s Tyrosine …Read More >

Resource Type: Presentation Video
Resource Topic: Biochemical Assays Biophysical Assays Discovery Chemistry Fragment-Based Drug Discovery Hit-to-Lead Lead Optimization Mass Spectrometry-based Assays Screening Libraries Small Molecules Structural Biology

VIEW

Discovery of Potent and Selective Dual Leucine Zipper Kinase/Leucine Zipper-Bearing Kinase Inhibitors

Dual leucine zipper kinase (DLK) and leucine zipper-bearing kinase (LZK) have emerged as key regulators of neuronal degeneration and axon growth.  WuXi AppTec scientists recently contributed to a research article in the Journal of Medicinal Chemistry demonstrating the use of ligand- and structure-based drug design approaches to discover an amino-pyrazine chemical series of DLK and …Read More >

Resource Type: Latest Science Publication
Resource Topic: Biochemical Assays Biomarkers Central Nervous System & Pain Discovery Chemistry Lead Optimization Small Molecules

VIEW

Computer-Aided Drug Discovery Services

Resource Type: Brochure
Resource Topic: DRUG DISCOVERY AND INNOVATION Hit Finding in silico services

VIEW

Discovery and preclinical evaluations of GST-HG131, a novel HBV antigen inhibitor for the treatment of chronic hepatitis B infection

Chronic HBV infection (CHB) is a major contributor to liver-related deaths worldwide. The ultimate endpoint of CHB treatment is sustained HBV surface antigen (HBsAg) loss. Here, we report the design of a series of HBV surface antigen inhibitors which promotes reduction of HBV antigens in vitro and in vivo. https://pubmed.ncbi.nlm.nih.gov/36089112/

Resource Type: Latest Science Publication
Resource Topic: Biochemical Assays Cell-based Assays Discovery Chemistry Hit-to-Lead Infectious Diseases Lead Optimization Liver Diseases Small Molecules

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!